Develops artificial heart valves designed for aortic and mitral replacements, featuring low thrombogenicity, lifelong durability, and a low acoustic signature, as demonstrated in preclinical studies. These valves address the unmet need for safer, longer-lasting options in patients of all ages, including children, reducing complications associated with current treatments.
Funding
$22.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current artificial heart valves have limitations in terms of durability, risk of blood clot formation (thrombogenicity), and acoustic signature, potentially leading to complications and reduced quality of life for patients, including children. These limitations necessitate frequent monitoring and potential re-interventions.
Solution
Novostia is developing a new generation of artificial heart valves designed for aortic and mitral replacements, addressing the shortcomings of existing options. The valves are engineered for low thrombogenicity to minimize the risk of blood clots, lifelong durability to reduce the need for replacements, and a low acoustic signature for improved patient comfort. Preclinical studies have demonstrated the potential of these valves to offer safer and longer-lasting solutions for patients of all ages.
Target Audience
The primary target audience includes patients requiring aortic or mitral valve replacements, as well as cardiac surgeons and medical professionals seeking improved valve options for their patients.
Features
- Designed for both aortic and mitral valve replacements.
- Engineered for low thrombogenicity to reduce the risk of blood clot formation.
- Optimized for lifelong durability, potentially minimizing the need for future replacements.
- Designed with a low acoustic signature to improve patient comfort.
- Intended for patients of all ages, including children.
- Investigational device currently undergoing preclinical evaluation.